Vericel/$VCEL

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Vericel

Vericel Corp is a fully integrated, commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.

Ticker

$VCEL
Sector
Primary listing

Employees

357

Vericel Metrics

BasicAdvanced
$1.7B
252.64
$0.13
1.39
-

What the Analysts think about Vericel

Analyst ratings (Buy, Hold, Sell) for Vericel stock.

Bulls say / Bears say

Vericel reported record Q1 2025 total net revenue of $52.6 million, driven by a 15% increase in MACI revenue to $46.3 million (Nasdaq).
NexoBrid net revenue jumped 207% year-over-year to $1.3 million and 31% sequentially in Q1, reflecting strong uptake in severe burn care therapies (Nasdaq).
Vericel raised its full-year 2025 profitability guidance, reaffirming 20–23% revenue growth and increasing its gross margin target to 74% and adjusted EBITDA margin to 26% (Nasdaq).
Vericel’s net loss widened to $11.2 million in Q1 2025, compared to a loss of $3.9 million in Q1 2024, underscoring continued unprofitability in the near term (Nasdaq).
Operating expenses rose to $49.1 million in Q1 2025 from $40.8 million a year earlier, a 20% increase that may pressure future margins (Nasdaq).
Epicel revenue fell to $5.0 million in Q1 2025, down from $10.7 million in the same period last year, indicating slower recovery in the burn care segment (Nasdaq).
Data summarised monthly by Lightyear AI. Last updated on 5 Oct 2025.

Vericel Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

Vericel Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $VCEL

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events
FAQs
Buy Vericel stock | $VCEL Share Price | Lightyear